[HTML][HTML] Korean practice guideline for gastric cancer 2018: an evidence-based, multi-disciplinary approach

DW Group, R Panel… - Journal of gastric …, 2019 - ncbi.nlm.nih.gov
Background Gastric cancer is the most common cancer and the fourth most common cause
of cancer death in South Korea [1]. Despite the large number of gastric cancer patients …

Surgical management of gastric cancer: a review

GZ Li, GM Doherty, J Wang - JAMA surgery, 2022 - jamanetwork.com
Importance Surgery plays a critical role in the management of all stages of gastric cancer.
Observations For patients with early gastric cancer and low risk of lymph node metastasis …

Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

F Lordick, F Carneiro, S Cascinu, T Fleitas… - Annals of …, 2022 - annalsofoncology.org
More than 1 million (1 089 103) new cases of gastric cancer were estimated globally in
2020, resulting in 768 793 deaths. 1 These burden estimates will continue to increase due to …

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

EC Smyth, M Verheij, W Allum… - Annals of …, 2016 - annalsofoncology.org
Almost one million (951 600) new cases of gastric cancer were diagnosed globally in 2012,
resulting in∼ 723 100 deaths [1]. Of these∼ 140 000 cases and∼ 107 000 deaths occurred …

A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study

JG Scott, A Berglund, MJ Schell, I Mihaylov… - The lancet …, 2017 - thelancet.com
Background Despite its common use in cancer treatment, radiotherapy has not yet entered
the era of precision medicine, and there have been no approaches to adjust dose based on …

[PDF][PDF] Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial

V Noronha, A Joshi, VM Patil, J Agarwal… - Journal of Clinical …, 2018 - academia.edu
Purpose Chemoradiation with cisplatin 100 mg/m2 given once every 3 weeks is the
standard of care in locally advanced head and neck squamous cell cancer (LAHNSCC) …

[HTML][HTML] A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients …

SH Park, DH Lim, TS Sohn, J Lee, DY Zang, ST Kim… - Annals of …, 2021 - Elsevier
Background Adjuvant chemotherapy and chemoradiotherapy are some of the standards of
care for gastric cancer (GC). The Adjuvant chemoRadioTherapy In Stomach Tumors …

Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer

Y Zeng, RU Jin - Seminars in cancer biology, 2022 - Elsevier
Gastric cancer is a major source of global cancer mortality with limited treatment options and
poor patient survival. As our molecular understanding of gastric cancer improves, we are …

Medical management of gastric cancer: a 2017 update

N Charalampakis, P Economopoulou… - Cancer …, 2018 - Wiley Online Library
Gastric cancer remains a considerable health burden throughout the world. The Cancer
Genome Atlas (TCGA) analysis has recently unveiled 4 genotypes of gastric cancer with …

CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent …

AE Slagter, EPM Jansen, HWM van Laarhoven… - Bmc Cancer, 2018 - Springer
Background Although radical surgery remains the cornerstone of cure in resectable gastric
cancer, survival remains poor. Current evidence-based (neo) adjuvant strategies have …